🔎 Trials Near Me

Home › Macular Degeneration › Florida › Fort Lauderdale

Macular Degeneration clinical trials in Fort Lauderdale, FL

5 studies for Macular Degeneration are looking for participants at sites in and around Fort Lauderdale (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

RecruitingPhase 2/3
  • Retina Group of Florida (Site 070), Fort Lauderdale
Ages 50 and older · All sexes · Updated Oct 2, 2026 · NCT07440225

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

RecruitingPhase 2/3
  • Retina Group of Florida, Fort Lauderdale
Ages 60 and older · All sexes · Updated Sep 30, 2026 · NCT06635148

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

RecruitingPhase 3
  • Retina Group of Florida, Fort Lauderdale
Ages 50 to 85 · All sexes · Updated Sep 18, 2026 · NCT06541704

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

RecruitingPhase 1/2
  • Retina Group of Florida, Fort Lauderdale
Ages 50 and older · All sexes · Updated Aug 21, 2026 · NCT05197270

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

RecruitingPhase 2
  • Adverum site 176, Fort Lauderdale
Ages 50 and older · All sexes · Updated Aug 5, 2026 · NCT07630649

About Macular Degeneration

Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.

More about Macular Degeneration on MedlinePlus

Macular Degeneration trials in other cities

Other studies in Fort Lauderdale

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.